2316
document
Gastric carcinoma : expression of c-erbB-2/neu oncoprotein , epidermal growth factor receptor , cathepsin D , progesterone receptor and tumor associated glycoprotein-72 in different histological types . OBJECTIVE Gastric carcinoma can be divided into two main histological and clinical types : diffuse and intestinal . The aim of this study was to investigate the expression of neu/c-erbB-2 oncoprotein , epidermal growth factor receptor ( EGFR ) , cathepsin D ( catD ) , progesterone receptor ( PR ) and tumor-associated glycoprotein-72 ( TAG-72 ) in gastric carcinoma of these histological types . METHOD In this randomized , prospective study we analyzed 85 biopsy samples from patients with gastric adenocarcinoma . The control group consisted of 40 specimens from normal gastric mucosa . Neu oncoprotein and PR were determined by ELISA . CatD and TAG-72 were quantified with immunoradiometric ( IRMA ) methods , and EGFR were studied by radioimmunoassay ( RIA ) . RESULTS Neu , EGFR , catD and TAG-72 concentrations were higher in the tumoral group ( p = 0.02 , p = 0.00001 , p = 0.002 and p = 0.007 , respectively ) . In diffuse adenocarcinomas , catD and PR expression was increased ( p = 0.01 and p = 0.04 respectively ) , whereas TAG-72 concentration , which correlated with neu ( r = 0.57 ) , was higher in the intestinal type ( p = 0.04 ) . No significant differences in EGFR and neu concentrations were seen between the two histological types . CONCLUSIONS The higher PR and catD concentrations in diffuse adenocarcinomas , and the overexpression of TAG-72 in the intestinal type , support the existence of two modes of gastric carcinogenesis .
2317
Intervention_Pharmacological
neu/c-erbB-2 oncoprotein
2318
Intervention_Physical
ELISA
2319
Outcome_Physical
expression of c-erbB-2/neu oncoprotein
2320
Outcome_Physical
epidermal growth factor receptor
2321
Outcome_Physical
cathepsin D , progesterone receptor
2322
Outcome_Physical
tumor associated glycoprotein-72
2323
Outcome_Physical
expression of neu/c-erbB-2 oncoprotein
2324
Outcome_Physical
epidermal growth factor receptor ( EGFR )
2325
Outcome_Physical
cathepsin D ( catD )
2326
Outcome_Physical
progesterone receptor ( PR )
2327
Outcome_Physical
tumor-associated glycoprotein-72 ( TAG-72 )
2328
Outcome_Physical
Neu oncoprotein
2329
Outcome_Physical
PR
2330
Outcome_Other
ELISA
2331
Outcome_Physical
CatD
2332
Outcome_Physical
TAG-72
2333
Outcome_Other
immunoradiometric ( IRMA ) methods
2334
Outcome_Physical
EGFR
2335
Outcome_Other
radioimmunoassay ( RIA )
2336
Outcome_Physical
Neu
2337
Outcome_Physical
EGFR
2338
Outcome_Physical
catD
2339
Outcome_Physical
TAG-72
2340
Outcome_Physical
catD
2341
Outcome_Physical
PR expression
2342
Outcome_Physical
TAG-72 concentration
2343
Outcome_Physical
neu
2344
Outcome_Physical
EGFR
2345
Outcome_Physical
neu
2346
Outcome_Physical
PR
2347
Outcome_Physical
catD concentrations
2348
Outcome_Physical
TAG-72
2349
Participant_Condition
Gastric carcinoma
2350
Participant_Condition
Gastric carcinoma
2351
Participant_Condition
gastric adenocarcinoma